A global virtual event dedicated to the latest heart failure treatment strategies to support better patient outcomes
A global virtual event dedicated to the latest heart failure treatment strategies to support better patient outcomes
Translational Medicine Academy (TMA) in partnership with Radcliffe Cardiology are delighted to announce the return of e-SPACE Heart Failure (HF) to be held 23-24 October 2026.
e-SPACE Heart Failure 2026 will once again offer high-quality, free virtual education – maximising global reach while delivering both international and regional perspectives. The expertly designed programme will delve into how leading clinicians are translating heart failure guidelines into real-world practice and will provide the latest insights into patient profiling for personalised heart failure therapy.
Building on the outstanding success of previous years, this event continues to unite TMA’s mission to deliver continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
Driven by this shared expertise in educational programming and delivery and led by a world-renowned international faculty, e-SPACE Heart Failure 2026 is designed to help you achieve optimal clinical outcomes in heart failure management.
(Please note this programme is subject to change)
Day 1
Meet the Expert
Meet The Expert
Plenary Session
Session 1 - The 2026 Heart Failure Guidelines: What Will Change My Practice
Chairs: Andrew Coats, Sotiria Liori
-
New Definitions, Classification and the Updated Diagnostic Pathway - Marco Metra
-
GDMT Sequencing and Rapid Up-Titration: From STRONG-HF to Routine Care - Mattia Arrigo
-
Foundational Therapy Across the Ejection-Fraction Spectrum
-
GDMT and Device Therapies - Rudolf De Boer
-
Panel Discussion
Meet the Expert
Meet The Expert
Plenary Session
Session 2 - HFrEF in 2026: Beyond the Four Pillars
Chairs: Mitja Lainscak, Dirk van Veldhuisen
-
The Four Pillars in Real-World Practice: Are We Actually There Yet? - Lisa Anderson
-
Digitoxin After DIGIT-HF: Back on the Table? - Johann Bauersachs
-
Vericiguat After VICTOR: Who Benefits, and When? - Faiez Zannad
-
HFimpEF: Recovery, Remission and the Case for (Not) Withdrawing Therapy - Ankeet Bhatt
-
Panel Discussion
Meet the Expert
Meet The Expert
Meet the Expert
Meet The Expert
Plenary Session
Session 3 - Cardiorenal Syndrome in 2026
Chairs: Gerasimos Filippatos, Francesca Musella
-
Beyond eGFR: Assessing and Monitoring Kidney Risk in Heart Failure - James Burton
-
Chronic Kidney Disease in HF: Managing the Overlap - Ana Cebrián Cuenca
-
Hyperkalaemia as a Barrier to Guideline-Directed Therapy - Tina Marvasti
-
Potassium Binders and Finerenone: Enabling and Protecting RAAS/MRA Therapy - Hiddo Heerspink
-
Panel Discussion
Meet the Expert
Meet The Expert
Plenary Session
Session 4 - HFpEF: One Syndrome, Many Phenotypes
Chairs: Shahzeb Khan, Abhinav Gupta
-
Finding HFpEF Earlier: Diagnostic Algorithms and Risk Scores - Cristina Gavina
-
Foundational Therapy in HFpEF: SGLT2 Inhibitors and Finerenone (FINEARTS-HF) - Muthiah Vaduganathan
-
MASH/MASLD and HFpEF
-
Arrhythmias in HFpEF - Javed Butler
-
Panel Discussion
Meet the Expert
Meet The Expert
Meet the Expert
Meet The Expert
Plenary Session
Session 5 - CKM Disease and Heart Failure- Obesity is Everywhere
Chair: Donna Ryan, Clara Ines Saldarriaga
-
AHA ACC CKM Guidelines - Chiadi Ndumele
-
Obesity-Related Heart Failure: Mechanisms and Epidemiology - Naveed Sattar
-
The Pipeline: Oral GLP-1, Dual and Triple Agonists - Dame Melanie Davies
-
Weight Loss, Muscle and Body Composition: Protecting the Muscle - Stefan Anker
-
Panel Discussion
Meet the Expert
Meet The Expert
Plenary Session
Session 6 - Cardiomyopathies and Cardiac Amyloidosis in 2026
Chair:
-
A Rational Diagnostic Pathway for the Cardiomyopathies - Arnt Kristen
-
Cardiac Amyloidosis: When to Suspect and How to Confirm - Fabian Knebel
-
ATTR-CM Therapies: Stabilisers, Silencers and What Comes Next - Laura Obici
-
Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors in Practice - Ahmad Masri
-
Panel Discussion
Day 2
Meet the Expert
Meet The Expert
Plenary Session
Session 7 - Rhythm Management and Device Therapies in Heart Failure
Chairs: John Cleland, Stefan Anker
-
Sudden Cardiac Death Prevention in HFrEF: Is the ICD Still Needed in 2026?
-
CRT and Conduction System Pacing: Choosing the Right Strategy
-
Cardiac Contractility Modulation and Device-Based Neuromodulation - Jürgen Kuschyk
-
Interatrial Shunt Devices and Sleep-Disordered Breathing: Where Do They Fit? - William Abraham
-
Panel Discussion
Meet the Expert
Meet The Expert
Plenary Session
Session 8 - Valvular Heart Disease in Heart Failure
Chair: Karl-Patrik Kresoja, Antonio Cannata
-
Functional Mitral Regurgitation: TEER and the Evolving Evidence - Gregg Stone
-
Tricuspid Regurgitation in HF: Repair, Replacement or Medical Therapy
-
Carillon for Functional MR: Patient Selection and Place in Therapy - Klaus Witte
-
The Heart Team Approach to the Heart Failure Patient - Karl Toischer
-
Panel Discussion
Meet the Expert
Meet The Expert
Plenary Session
Session 9 - Significant Problem of Vulnerable HF Patient
Chairs: Ovidiu Chioncel, Ewa Jankowska
Optimizing Heart Failure Care in Older Patients - Harriette van Spall
Iron Deficiency Across the EF Spectrum: FAIR-HF2 and the Meta-Analytic Picture - Piotr Ponikowski
Advanced HF: Recognising the Tipping Point and Getting Referral Timing Right - Maria Crespo-Leiro
LVAD and Transplant in the Modern Era: Candidacy and Outcomes - Mandeep Mehra
Panel Discussion
Meet the Expert
Meet The Expert
Plenary Session
Session 10 - Delivering Better Heart Failure Care and Innovation in 2026
Chairs: Shelley Zieroth, Fausto Pinto
-
Telemonitoring and Remote Management: What Works and for Whom - Nicolas Girerd
-
Polypharmacy, Adherence and Persistence: The Implementation Reality - Giuseppe Rosano
-
Multidisciplinary HF Care and Transitions of Care - Tiny Jaarsma
-
Preventing Heart Failure - Norbert Frey
-
Panel Discussion
William Abraham
The Ohio State University Wexner Medical Center, Columbus, US
Lisa Anderson
St George’s Hospital, London, UK
Stefan Anker
Charité Campus Virchow-Klinikum, Berlin, DE
Mattia Arrigo
Ospedale Regionale di Lugano, Lugano, CH
Johann Bauersachs
Hannover Medical School, Hannover, DE
Ankeet Bhatt
Kaiser San Francisco Medical Center, San Francisco, US
James Burton
University of Leicester, Leicester, UK
Javed Butler
Baylor Scott & White Health, Dallas, US
Antonio Cannata
King's College London, London, UK
Ovidiu Chioncel
University of Medicine Carol Davila, Bucharest, RO
John Cleland
University of Glasgow, Glasgow, UK
Andew Coats
Heart Research Institute, Sydney, AU
Maria Crespo-Leiro
University of A Coruña (UDC), Coruna, ES
Ana Cebrián Cuenca
Murcian Health Service, Cartagena , ES
Dame Melanie Davies
University of Leicester, Leicester, UK
Rudolf De Boer
University of Groningen, Groningen, NL
Gerasimos Filippato
Attikon University Hospital, Athens, GR
Marianna Fontana
University College London (UCL), London, UK
Norbert Frey
University of Heidelberg, Heidelberg, DE
Cristina Gavina
University of Porto, Porto, PT
Nicolas Girerd
University Hospital of Nancy, Nancy, FR
Abhinav Gupta
SDDM Hospital, Jammu, IN
Hiddo Heerspink
University of Groningen, Groningen, NL
Tiny Jaarsma
Linköping University, Linköping, SE
Ewa Jankowska
Wrocław Medical University, Wroclaw, PL
Shahzeb Khan
Baylor Scott & White Health, Texas, US
Prof Fabian Knebel
Sana Klinikum Lichtenberg, Berlin, DE
Karl-Patrik Kresoja
University Medical Centre of the Johannes Gutenberg University, Mainz, DE
Arnt Kristen
University of Heidelberg, Heidelberg, DE
Jürgen Kuschyk
University Medical Centre of Mannheim, Mannheim, DE
Mitja Lainscak
University of Ljubljana, Ljubljana, SI
Carolyn Lam
National Heart Centre Singapore, Singapore, SG
Tina Marvasti
University of Toronto, Toronto, CA
Ahmad Masri
Oregon Health & Science University Medical Group, Portland, US
Mandeep Mehra
Brigham and Women's Hospital, Boston, US
Marco Metra
University of Brescia, Bresica, IT
Francesca Musella
Karolinska Institute, Stockholm, SE
Chiadi Ndumele
Johns Hopkins University, Baltimore, US
Laura Obici
IRCCS Fondazione Policlinico San Matteo, Pavia, IT
Fausto Pinto
Santa Maria University Hospital, Lisbon, PT
Piotr Ponikowski
Wroclaw Medical University, Wroclaw, PL
Giuseppe Rosano
St George's University Medical School, London, UK
Donna Ryan
Pennington Biomedical Research Center, Baton Rouge, US
Clara Ines Saldarriaga
University of Antioquia, Medellín, CO
Naveed Sattar
University of Glasgow, Glasgow, UK
Gianluigi Savarese
Karolinska Institutet, Stockholm, SE
Gregg Stone
Mount Sinai Heart Health System, New York, US
Karl Toischer
University of Göttingen, Göttingen, DE
Muthiah Vaduganathan
Brigham and Women's Hospital, Boston, US
Harriette Van Spall
McMaster University, Hamilton, CA
Dirk van Veldhuisen
University of Groningen, Groningen, NL
Klaus Witte
University of Leeds, Leeds, UK
Faiez Zannad
University of Lorraine, Nancy, FR
Shelley Zieroth
University of Manitoba, Winnipeg, CAReview the burden of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) as one of the leading causes of disability and mortality worldwide
Understand the latest guideline recommendations and discuss their applicability according to patients phenotypes
Discuss the implementation in clinical practice of the four foundational therapies and additional drugs and devices to improve patient outcomes
Develop a comprehensive understanding of best practices for the screening, diagnosis and management of the patient with heart failure and comorbidities
Translate the findings of recent studies and guidelines into optimal patient management
Heart Failure Specialists
General Cardiologists
General Practitioners (GPs)
Nephrologists
Diabetologists / Endocrinologists
Pharmacists and Other Allied Healthcare Professionals
Sponsors




If you’re interested in becoming an educational partner or sponsor at this event, please contact sales@radcliffe-group.com
About Translational Medicine Academy
Our ambition at the Translational Medicine Academy® (TMA) is to bring medical findings from bench to bedside and into the working lives of physicians and the care of patients. In seeking to improve therapeutic approaches, TMA works with its International Scientific Advisory Board on Critical Mission Areas® of public health importance in domains where there are educational shortcomings among physicians and unmet healthcare needs among patients. Gathered around a Scientific Advisory Board of experts, the Translational Medicine Academy is an international non-profit Foundation with headquarter in Basel, and offices in Paris, and the US. TMA’s funding includes private donations from individuals and educational grants from governments, non-governmental organizations and corporations. For more information on TMA, please visit www.tmacademy.org.
About Radcliffe Cardiology
We are Radcliffe, a knowledge network for the cardiovascular community
We’re here to bring cardiovascular knowledge, insight and innovation to life for clinicians around the world, using our communications and creative expertise, our platforms and connections across the community to help transform theory into practice faster and more effectively.
We bring medical knowledge to life
From great science writing and smart journal editing, the curation of evidence based and peer-reviewed content, to engaging new formats that cut through the noise, we believe that communication is at the heart of great healthcare.
Our work is underpinned by 3 core principles:
We build on the best science
We work hands-on with our community
We bring fresh thinking
Our promise is that we’ll equip you with the latest knowledge and skills you need, to do the best for your patients.
For more information on Radcliffe Cardiology, please visit www.radcliffecardiology.com

